{"id":346235,"date":"2026-11-13T12:40:33","date_gmt":"2026-11-13T07:10:33","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=346235"},"modified":"2026-11-13T12:40:33","modified_gmt":"2026-11-13T07:10:33","slug":"hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/","title":{"rendered":"3 Hospitals Chain, Engineering and Construction Major and Pharmaceuticals Maker Stocks With a Strong Future Roadmap: Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma: ROE of 10.5% to 23.3% and FY22 to FY26 revenue CAGR of 12.4% to 16.4%. Prices as of 12 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three hospital, engineering and pharma stocks to watch are Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma. Their return on equity ranges from 10.5% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 16.4%. Ajanta Pharma has the highest return on equity at 23.3%, while Larsen &#038; Toubro has the fastest revenue growth at 16.4% a year. Prices are based on the 12 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Hospital, engineering and pharma stocks offer a focused view of a sector where demand keeps widening. Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma cover a hospitals chain, an engineering and construction major and a pharmaceuticals maker.<\/p>\n<p>This list covers three hospital, engineering and pharma stocks with complete current figures: Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#What_Are_Hospital_Engineering_and_Pharma_Stocks\" title=\"What Are Hospital, Engineering and Pharma Stocks?\">What Are Hospital, Engineering and Pharma Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Hospital_Engineering_and_Pharma_Stocks_at_a_Glance\" title=\"Hospital, Engineering and Pharma Stocks at a Glance\">Hospital, Engineering and Pharma Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Why_Do_Hospital_Engineering_and_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Hospital, Engineering and Pharma Stocks Have a Strong Roadmap in India?\">Why Do Hospital, Engineering and Pharma Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Why_Fortis_Healthcare_Features_Among_These_Hospital_Engineering_and_Pharma_Stocks\" title=\"Why Fortis Healthcare Features Among These Hospital, Engineering and Pharma Stocks\">Why Fortis Healthcare Features Among These Hospital, Engineering and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Why_Larsen_Toubro_Features_Among_These_Hospital_Engineering_and_Pharma_Stocks\" title=\"Why Larsen &#038; Toubro Features Among These Hospital, Engineering and Pharma Stocks\">Why Larsen &#038; Toubro Features Among These Hospital, Engineering and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Why_Ajanta_Pharma_Features_Among_These_Hospital_Engineering_and_Pharma_Stocks\" title=\"Why Ajanta Pharma Features Among These Hospital, Engineering and Pharma Stocks\">Why Ajanta Pharma Features Among These Hospital, Engineering and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Fortis_Healthcare_vs_Larsen_Toubro_vs_Ajanta_Pharma_on_Key_Financials\" title=\"Fortis Healthcare vs Larsen &#038; Toubro vs Ajanta Pharma on Key Financials\">Fortis Healthcare vs Larsen &#038; Toubro vs Ajanta Pharma on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Key_Risks_to_Check_Before_Investing_in_Hospital_Engineering_and_Pharma_Stocks\" title=\"Key Risks to Check Before Investing in Hospital, Engineering and Pharma Stocks\">Key Risks to Check Before Investing in Hospital, Engineering and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Final_Thoughts_on_Hospital_Engineering_and_Pharma_Stocks\" title=\"Final Thoughts on Hospital, Engineering and Pharma Stocks\">Final Thoughts on Hospital, Engineering and Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#What_are_hospital_engineering_and_pharma_stocks\" title=\"What are hospital, engineering and pharma stocks?\">What are hospital, engineering and pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Which_hospital_engineering_and_pharma_stocks_are_covered_in_this_list\" title=\"Which hospital, engineering and pharma stocks are covered in this list?\">Which hospital, engineering and pharma stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Why_do_hospital_engineering_and_pharma_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do hospital, engineering and pharma stocks have a strong future roadmap in India?\">Why do hospital, engineering and pharma stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#How_has_Fortis_Healthcare_performed_financially\" title=\"How has Fortis Healthcare performed financially?\">How has Fortis Healthcare performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#How_has_Larsen_Toubro_performed_financially\" title=\"How has Larsen &#038; Toubro performed financially?\">How has Larsen &#038; Toubro performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#How_has_Ajanta_Pharma_performed_financially\" title=\"How has Ajanta Pharma performed financially?\">How has Ajanta Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#What_risks_should_investors_check_before_buying_hospital_engineering_and_pharma_stocks\" title=\"What risks should investors check before buying hospital, engineering and pharma stocks?\">What risks should investors check before buying hospital, engineering and pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker-stocks-roadmap-escarpment-list\/#Is_this_list_of_hospital_engineering_and_pharma_stocks_investment_advice\" title=\"Is this list of hospital, engineering and pharma stocks investment advice?\">Is this list of hospital, engineering and pharma stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Hospital_Engineering_and_Pharma_Stocks\"><\/span><strong>What Are Hospital, Engineering and Pharma Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hospital, engineering and pharma stocks are listed companies that run multi speciality hospitals and diagnostic centres, build large infrastructure, defence and energy projects, and make branded medicines for chronic care. Their earnings depend on patient volumes, project orders and medicine demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Hospital_Engineering_and_Pharma_Stocks_at_a_Glance\"><\/span><strong>Hospital, Engineering and Pharma Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/fortis\/fortis-healthcare-ltd-share-price-today\">Fortis Healthcare<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">760<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">55,554<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">51.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.35<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lt\/larsen-and-toubro-ltd-share-price-today\">Larsen &#038; Toubro<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,159.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">501,514<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.15<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,324<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">41,241<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Fortis Healthcare trades at a P\/E below the industry P\/E, while Larsen &#038; Toubro and Ajanta Pharma trade above it, which reflects the growth the market already expects. Readers comparing hospital, engineering and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital, engineering and pharma stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Hospital_Engineering_and_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Hospital, Engineering and Pharma Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hospital, engineering and pharma stocks have a strong roadmap in India because rising need for quality hospital care, heavy infrastructure and defence spending and growing chronic care demand keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Hospitals.<\/strong> Families seek quality specialist care.<\/li>\n<li><strong>Engineering and construction.<\/strong> Large projects need proven builders.<\/li>\n<li><strong>Pharmaceuticals.<\/strong> Chronic patients need regular medicines.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Fortis_Healthcare_Features_Among_These_Hospital_Engineering_and_Pharma_Stocks\"><\/span><strong>Why Fortis Healthcare Features Among These Hospital, Engineering and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the hospital, engineering and pharma stocks on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.<\/p>\n<p>The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P\/E of 51.9, below the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.<\/p>\n<p><strong>What to watch:<\/strong> Track bed additions, occupancy and revenue per occupied bed.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Larsen_Toubro_Features_Among_These_Hospital_Engineering_and_Pharma_Stocks\"><\/span><strong>Why Larsen &#038; Toubro Features Among These Hospital, Engineering and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the healthcare network, construction major and medicine shares on this list, Larsen and Toubro is a Mumbai-based engineering and construction conglomerate that builds infrastructure, energy and defence projects and also runs technology services, financial services and electronics businesses.<\/p>\n<p>Revenue rose from Rs 158,788 crore in FY22 to Rs 291,635 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 10,291 crore in FY22 to Rs 19,159 crore in FY26, which works out to a compound annual growth rate of 16.8%.<\/p>\n<p>In the June 2026 quarter, revenue grew 8.1% year on year to Rs 70,318 crore, while net profit rose 15.2% to Rs 4,983 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 1.15 and a market capitalisation of Rs 501,514 crore. The stock trades at a P\/E of 25.6, above the industry P\/E of 21.9.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a very large order book across infrastructure, energy and hydrocarbon projects, supported by government capital spending. Its growing technology and green energy businesses widen its sources of growth.<\/p>\n<p><strong>What to watch:<\/strong> Monitor order inflows, project execution and government infrastructure spending.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ajanta_Pharma_Features_Among_These_Hospital_Engineering_and_Pharma_Stocks\"><\/span><strong>Why Ajanta Pharma Features Among These Hospital, Engineering and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.<\/p>\n<p>In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.<\/p>\n<p>Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the pace of new launches in branded markets and the momentum in the United States generics business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Fortis_Healthcare_vs_Larsen_Toubro_vs_Ajanta_Pharma_on_Key_Financials\"><\/span><strong>Fortis Healthcare vs Larsen &#038; Toubro vs Ajanta Pharma on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three hospital, engineering and pharma stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Fortis Healthcare<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,745<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,178<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,064<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Larsen &#038; Toubro<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">158,788<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">291,635<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19,159<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,457<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,625<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,056<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ajanta Pharma posts the highest return on equity in this group at 23.3%. Larsen &#038; Toubro combines the largest FY26 revenue at Rs 291,635 crore with the fastest revenue growth, a 16.4% compound annual rate. A useful habit with hospital, engineering and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Fortis Healthcare<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,182<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,560<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Larsen &#038; Toubro<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">65,036<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">70,318<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,329<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,697<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Hospital_Engineering_and_Pharma_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Hospital, Engineering and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these hospital, engineering and pharma stocks, the main points are: Long-term healthcare network, construction major and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Capacity ramp up.<\/strong> New hospitals take time to fill beds and reach full returns.<\/li>\n<li><strong>Order timing.<\/strong> Project awards can shift between periods.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter hospital, engineering and pharma stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Hospital_Engineering_and_Pharma_Stocks\"><\/span><strong>Final Thoughts on Hospital, Engineering and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hospital, engineering and pharma stocks reward patient research into demand, execution and financial strength. Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma each have a clear plan to grow. Based on the 12 November 2026 close, Fortis Healthcare trades at Rs 760, Larsen &#038; Toubro at Rs 4,159.2 and Ajanta Pharma at Rs 3,324. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these hospital, engineering and pharma stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track hospital, engineering and pharma stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_hospital_engineering_and_pharma_stocks\"><\/span><strong>What are hospital, engineering and pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Hospital, engineering and pharma stocks are listed companies that run multi speciality hospitals and diagnostic centres, build large infrastructure, defence and energy projects, and make branded medicines for chronic care. Their earnings depend on patient volumes, project orders and medicine demand. This list looks at three of them, Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_hospital_engineering_and_pharma_stocks_are_covered_in_this_list\"><\/span><strong>Which hospital, engineering and pharma stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma. Based on the 12 November 2026 close, Fortis Healthcare traded at Rs 760, Larsen &#038; Toubro at Rs 4,159.2 and Ajanta Pharma at Rs 3,324. Their return on equity ranges from 10.5% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 16.4%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_hospital_engineering_and_pharma_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do hospital, engineering and pharma stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Hospital, engineering and pharma stocks have a strong roadmap in India because rising need for quality hospital care, heavy infrastructure and defence spending and growing chronic care demand keep widening the market for these companies. The main drivers are as follows. Hospitals. Families seek quality specialist care. Engineering and construction. Large projects need proven builders. Pharmaceuticals. Chronic patients need regular medicines. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Fortis_Healthcare_performed_financially\"><\/span><strong>How has Fortis Healthcare performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P\/E of 51.9, below the industry P\/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Larsen_Toubro_performed_financially\"><\/span><strong>How has Larsen &#038; Toubro performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 158,788 crore in FY22 to Rs 291,635 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 10,291 crore in FY22 to Rs 19,159 crore in FY26, which works out to a compound annual growth rate of 16.8%. In the June 2026 quarter, revenue grew 8.1% year on year to Rs 70,318 crore, while net profit rose 15.2% to Rs 4,983 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 1.15 and a market capitalisation of Rs 501,514 crore. The stock trades at a P\/E of 25.6, above the industry P\/E of 21.9. Looking ahead, the company has a very large order book across infrastructure, energy and hydrocarbon projects, supported by government capital spending. Its growing technology and green energy businesses widen its sources of growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ajanta_Pharma_performed_financially\"><\/span><strong>How has Ajanta Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_hospital_engineering_and_pharma_stocks\"><\/span><strong>What risks should investors check before buying hospital, engineering and pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying hospital, engineering and pharma stocks. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Order timing. Project awards can shift between periods. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_hospital_engineering_and_pharma_stocks_investment_advice\"><\/span><strong>Is this list of hospital, engineering and pharma stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are hospital, engineering and pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Hospital, engineering and pharma stocks are listed companies that run multi speciality hospitals and diagnostic centres, build large infrastructure, defence and energy projects, and make branded medicines for chronic care. Their earnings depend on patient volumes, project orders and medicine demand. This list looks at three of them, Fortis Healthcare, Larsen & Toubro and Ajanta Pharma, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which hospital, engineering and pharma stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Fortis Healthcare, Larsen & Toubro and Ajanta Pharma. Based on the 12 November 2026 close, Fortis Healthcare traded at Rs 760, Larsen & Toubro at Rs 4,159.2 and Ajanta Pharma at Rs 3,324. Their return on equity ranges from 10.5% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 16.4%.\"}},{\"@type\":\"Question\",\"name\":\"Why do hospital, engineering and pharma stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Hospital, engineering and pharma stocks have a strong roadmap in India because rising need for quality hospital care, heavy infrastructure and defence spending and growing chronic care demand keep widening the market for these companies. The main drivers are as follows. Hospitals. Families seek quality specialist care. Engineering and construction. Large projects need proven builders. Pharmaceuticals. Chronic patients need regular medicines. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Fortis Healthcare performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P\/E of 51.9, below the industry P\/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.\"}},{\"@type\":\"Question\",\"name\":\"How has Larsen & Toubro performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 158,788 crore in FY22 to Rs 291,635 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 10,291 crore in FY22 to Rs 19,159 crore in FY26, which works out to a compound annual growth rate of 16.8%. In the June 2026 quarter, revenue grew 8.1% year on year to Rs 70,318 crore, while net profit rose 15.2% to Rs 4,983 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 1.15 and a market capitalisation of Rs 501,514 crore. The stock trades at a P\/E of 25.6, above the industry P\/E of 21.9. Looking ahead, the company has a very large order book across infrastructure, energy and hydrocarbon projects, supported by government capital spending. Its growing technology and green energy businesses widen its sources of growth.\"}},{\"@type\":\"Question\",\"name\":\"How has Ajanta Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying hospital, engineering and pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying hospital, engineering and pharma stocks. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Order timing. Project awards can shift between periods. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of hospital, engineering and pharma stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hospital, Engineering and Pharma Stocks with a strong future roadmap: Fortis Healthcare, Larsen &#038; Toubro and Ajanta Pharma. Compare price, valuation, return on equity and revenue growth as of 12 November 2026.<\/p>\n","protected":false},"author":36,"featured_media":346234,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[13959,3803,23522,23521,7543,23257,15948,23524,23523],"class_list":["post-346235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-ajanta-pharma","tag-best-stocks","tag-construction-major-and-medicine-shares","tag-engineering-and-pharma-stocks","tag-fortis-healthcare","tag-healthcare-network","tag-hospital","tag-project-builder-and-formulations-stocks","tag-specialist-care"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["346234"],"rank_math_title":["Hospital, Engineering and Pharma Stocks"],"rank_math_description":["Compare 3 hospital, engineering and pharma stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 12 Nov 2026."],"rank_math_focus_keyword":["hospital, engineering and pharma stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-hospitals-chain-engineering-and-construction-major-and-pharmaceuticals-maker.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/346235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=346235"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/346235\/revisions"}],"predecessor-version":[{"id":346236,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/346235\/revisions\/346236"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/346234"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=346235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=346235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=346235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}